Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment
Bryan Oronsky, Neil Oronsky, Susan Knox
1RadioRx, Inc, 800 W El Camino Real, Suite 180, Mountain View CA 94040. jscicinski@radiorx.com.
Abstract:
Resistance to chemotherapy, biological and targeted therapies is an important clinical problem. Resistance can arise and/or be selected for multiple mechanisms of action. Unfortunately, acquired resistance to antitumor agents or regimens is nearly inevitable in all patients with metastatic disease. Until recently, it was believed that this resistance was unalterable and irreversible, rendering retreatment with the same or similar drugs futile in most cases. However, the introduction of epigenetic therapies, including HDAC inhibitors and DNA methyltransferase inhibitors (DNMTIs), has provided oncologists with new strategies to potentially overcome this resistance. For example, if chemoresistance is the product of multiple non-genetic alterations, which develop and accumulate over time in response to treatment, then the ability to epigenetically modify the tumor to reconfigure it back to its baseline non-resistant state, holds tremendous promise for the treatment of advanced, metastatic cancer. This minireview aims (1) to explore the potential mechanisms by which a group of small molecule agents including HDACs (entinostat and vorinostat), DNA hypomethylating agents such as the DNMTIs (decitabine (DEC), 5-azacytidine (5-AZA)) and redox modulators (RRx-001) may reprogram the tumors from a refractory to non-refractory state, (2) highlight some recent findings in this area, and (3) discuss the therapeutic potential of resensitization approaches with formerly failed chemotherapies.
Insights
Epigenetic therapies like HDAC inhibitors and DNMTIs can potentially reverse chemotherapy resistance in metastatic cancer. These agents may reprogram tumors, offering new hope for resensitizing patients to previously ineffective treatments.
Area of Science:
- Oncology
- Epigenetics
- Pharmacology
Background:
- Acquired resistance to chemotherapy, biological, and targeted therapies is a significant clinical challenge in metastatic cancer.
- This resistance was historically considered irreversible, limiting retreatment options.
- Epigenetic therapies offer novel strategies to potentially overcome established drug resistance.
Purpose of the Study:
- To explore mechanisms of small molecule agents in reprogramming tumors from a resistant to a non-resistant state.
- To highlight recent findings on epigenetic reprogramming for overcoming cancer resistance.
- To discuss the therapeutic potential of resensitization strategies with previously failed chemotherapies.
Main Methods:
- Review of literature on epigenetic modifiers including HDAC inhibitors (entinostat, vorinostat) and DNA methyltransferase inhibitors (DNMTIs) like decitabine (DEC) and 5-azacytidine (5-AZA).
- Exploration of redox modulators (RRx-001) in tumor reprogramming.
- Analysis of recent findings and therapeutic potential for resensitization approaches.
Main Results:
- Epigenetic agents may reverse non-genetic alterations contributing to chemoresistance.
- Small molecules can potentially reconfigure tumors to a non-resistant state.
- Resensitization approaches show promise for treating advanced metastatic cancer.
Conclusions:
- Epigenetic therapies hold significant promise for overcoming acquired resistance in metastatic cancer.
- Reprogramming tumors using agents like HDAC inhibitors, DNMTIs, and redox modulators can restore sensitivity to chemotherapy.
- This approach offers a potential strategy for retreatment in patients with advanced disease.
Related Concept Videos
Tumor Immunotherapy
Desensitization and Tachyphylaxis
Mitogens and the Cell Cycle
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Epigenetic Regulation
X-chromosome...


